http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#Head
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#assertion
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#provenance
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#pubinfo
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#assertion
http://purl.obolibrary.org/obo/DOID_2983
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2983
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00698
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association
http://www.w3.org/2000/01/rdf-schema#label
"Anuria, oliguria, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) are contraindications. Treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug. Because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38 to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent. For the same reason, the drug is contraindicated in neonates under one month of age. Nitrofurantoin Capsules, USP (monohydrate/ macrocrystals) are contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin. Nitrofurantoin Capsules, USP (monohydrate/ macrocrystals)are also contraindicated in those patients with known hypersensitivity to nitrofurantoin."
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00698
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#provenance
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#pubinfo
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#sig
http://purl.org/nanopub/x/hasSignature
ARdH/F/MUf6zo7jk7XyW0mn4JtOIrAvNJ+cpkXcqs5qsjk/zOFTxn25Lol1X2uYcUqA5ZBYoL07KYoeO3NLXIexXVye8U2dHJ8/YIIIH+J3PkveG4cHem5GihVkP2Rk2HqobMmNMwquPAYtx5wdEH3bdsTjPDDnybnSYUmnB2oc=
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
http://purl.org/dc/terms/created
2021-08-23T18:29:20.442+02:00
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY